Page 782 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

760 PART IV Specific Malignancies in the Small Animal Patient

329. Jeglum KA, Young KM, Barnsley K, et al.: Chemotherapy versus 349. Williams LE, Johnson JL, Hauck ML, et al.: Chemotherapy fol-
chemotherapy with intralymphatic tumor cell vaccine in canine lowed by half-body radiation therapy for canine lymphoma, J Vet
lymphoma, Cancer 61:2042–2050, 1988. Intern Med 18:703–709, 2004.
VetBooks.ir 330. Turek MM, Thamm DH, Mitzey A, et al.: Human granulocyte- 350. Williams LE, Pruitt AF, Thrall DE: Chemotherapy followed by
abdominal cavity irradiation for feline lymphoblastic lymphoma,
macrophage colony-stimulating factor DNA cationic-lipid com-
plexed autologous tumour cell vaccination in the treatment of
Vet Radiol Ultrasound 51:681–687, 2010.
canine B-cell multicentric lymphoma, Vet Comp Oncol 5:219–231, 351. George R, Smith A, Schleis S, et al.: Outcome of dogs with intra-
2007. nasal lymphoma treated with various radiation and chemotherapy
331. Gavazza A, Lubas G, Fridman A, et al.: Safety and efficacy of a protocols: 24 cases, Vet Radiol Ultrasound 57:306–312, 2016.
genetic vaccine targeting telomerase plus chemotherapy for the 352. Axiak SM, Carreras JK, Hahn KA, et al.: Hematologic changes
therapy of canine B-cell lymphoma, Hum Gene Ther 24:728–738, associated with half-body irradiation in dogs with lymphoma, J Vet
2013. Intern Med 20:1398–1401, 2006.
332. Peruzzi D, Gavazza A, Mesiti G, et al.: A vaccine targeting telom- 353. Dank G, Rassnick KM, Kristal O, et al.: Clinical characteristics,
erase enhances survival of dogs affected by B-cell lymphoma, Mol treatment, and outcome of dogs with presumed primary hepatic
Ther 18:1559–1567, 2010. lymphoma: 18 cases (1992-2008), J Am Vet Med Assoc 239:966–
333. Marconato L, Frayssinet P, Rouquet N, et al.: Randomized, pla- 971, 2011.
cebo-controlled, double-blinded chemoimmunotherapy clinical 354. Gustafson NR, Lana SE, Mayer MN, et al.: A preliminary assess-
trial in a pet dog model of diffuse large B-cell lymphoma, Clin ment of whole-body radiotherapy interposed within a chemother-
Cancer Res 20:668–677, 2014. apy protocol for canine lymphoma, Vet Comp Oncol 2:125–131,
334. Marconato L, Stefanello D, Sabattini S, et al.: Enhanced thera- 2004.
peutic effect of APAVAC immunotherapy in combination with 355. Appelbaum FR, Deeg HJ, Storb R, et al.: Marrow transplant stud-
dose-intense chemotherapy in dogs with advanced indolent B-cell ies in dogs with malignant lymphoma, Transplantation 39:499–
lymphoma, Vaccine 33:5080–5086, 2015. 504, 1985.
335. Sorenmo KU, Krick E, Coughlin CM, et al.: CD40-activated B 356. Warry EE, Willcox JL, Suter SE: Autologous peripheral blood
cell cancer vaccine improves second clinical remission and survival hematopoietic cell transplantation in dogs with T-cell lymphoma,
in privately owned dogs with non-Hodgkin’s lymphoma, PLoS One J Vet Intern Med 28:529–537, 2014.
6:e24167, 2011. 357. Willcox JL, Pruitt A, Suter SE: Autologous peripheral blood hema-
336. Mason NJ, Coughlin CM, Overley B, et al.: RNA-loaded CD40- topoietic cell transplantation in dogs with B-cell lymphoma, J Vet
activated B cells stimulate antigen-specific T-cell responses in dogs Intern Med 26:1155–1163, 2012.
with spontaneous lymphoma, Gene Ther 15:955–965, 2008. 358. Escobar C, Grindem C, Neel JA, et al.: Hematologic changes after
337. O’Connor CM, Sheppard S, Hartline CA, et al.: Adoptive T-cell total body irradiation and autologous transplantation of hemato-
therapy improves treatment of canine non-Hodgkin lymphoma poietic peripheral blood progenitor cells in dogs with lymphoma,
post chemotherapy, Sci Rep 2(249), 2012. Vet Pathol 49:341–343, 2012.
338. Panjwani MK, Smith JB, Schutsky K, et al.: Feasibility and safety of 359. Frimberger AE, Moore AS, Rassnick KM, et al.: A combination
RNA-transfected CD20-specific chimeric antigen receptor t cells in chemotherapy protocol with dose intensification and autologous
dogs with spontaneous B cell lymphoma, Mol Ther 24:1602–1614, bone marrow transplant (VELCAP-HDC) for canine lymphoma,
2016. J Vet Intern Med 20:355–364, 2006.
339. van Stee LL, Boston SE, Singh A, et al.: Outcome and prognostic 360. Rassnick KM, Moore AS, Collister KE, et al.: Efficacy of combina-
factors for canine splenic lymphoma treated by splenectomy (1995- tion chemotherapy for treatment of gastrointestinal lymphoma in
2011), Vet Surg 44:976–982, 2015. dogs, J Vet Intern Med 23:317–322, 2009.
340. Brooks MB, Matus RE, Leifer CE, et al.: Use of splenectomy in the 361. Frank JDRS, Kass PH, et al.: Clinical outcomes of 30 cases (1997-
management of lymphoma in dogs: 16 cases (1976-1985), J Am Vet 2004) of canine gastrointestinal lymphoma, J Am Anim Hosp Assoc
Med Assoc 191:1008–1010, 1987. 43:313–321, 2007.
341. Brown EM, Ruslander DM, Azuma C, et al.: A feasibility study of 362. Desmas I, Burton JH, Post G, et al.: Clinical presentation, treat-
low-dose total body irradiation for relapsed canine lymphoma, Vet ment and outcome in 31 dogs with presumed primary colorectal
Comp Oncol 4:75–83, 2006. lymphoma (2001-2013), Vet Comp Oncol 15:504–517, 2017.
342. Deeg HJ, Appelbaum FR, Weiden PL, et al.: Autologous marrow 363. Van den Steen N, Berlato D, Polton G, et al.: Rectal lymphoma
transplantation as consolidation therapy for canine lymphoma: effi- in 11 dogs: a retrospective study, J Small Anim Pract 53:586–591,
cacy and toxicity of various regimens of total body irradiation, Am J 2012.
Vet Res 46:2016–2018, 1985. 364. Long SN, Johnston PE, Anderson TJ: Primary T-cell lymphoma of
343. Gustafson NR, Lana SE, Mayer MN, et al.: A preliminary assess- the central nervous system in a dog, J Am Vet Med Assoc 218:719–
ment of whole-body radiotherapy interposed within a chemother- 722, 2001.
apy protocol for canine lymphoma, Vet Comp Oncol 2:125–131, 365. Deravi N, Berke O, Woods JP, et al.: Specific immunotypes of
2004. canine T cell lymphoma are associated with different outcomes, Vet
344. Lurie DM, Gordon IK, Theon AP, et al.: Sequential low-dose rate Immunol Immunopathol 2017(191):5–13, 2017.
half-body irradiation and chemotherapy for the treatment of canine 366. Risbon RE, de Lorimier LP, Skorupski K, et al.: Response of canine
multicentric lymphoma, J Vet Intern Med 23:1064–1070, 2009. cutaneous epitheliotropic lymphoma to lomustine (CCNU): a
345. Lurie DM, Kent MS, Fry MM, et al.: A toxicity study of low-dose retrospective study of 46 cases (1999-2004), J Vet Intern Med
rate half-body irradiation and chemotherapy in dogs with lym- 20:1389–1397, 2006.
phoma, Vet Comp Oncol 6:257–267, 2008. 367. Berlato D, Schrempp D, Van Den Steen N, et al.: Radiotherapy
346. Mayer MN, Larue SM: Radiation therapy in the treatment of in the management of localized mucocutaneous oral lymphoma in
canine lymphoma, Can Vet J 46:842–844, 2005. dogs: 14 cases, Vet Comp Oncol 10:16–23, 2012.
347. Meleo KA: The role of radiotherapy in the treatment of lymphoma 368. Holtermann N, Kiupel M, Kessler M, et al.: Masitinib monother-
and thymoma, Vet Clin North Am Small Anim Pract 27:115–129, apy in canine epitheliotropic lymphoma, Vet Comp Oncol 14(suppl
1997. 1):127–135, 2016.
348. Santoro D, Kubicek L, Lu B, et al.: Total skin electron therapy 369. Laprais A, Olivry T: Is CCNU (lomustine) valuable for treat-
as treatment for epitheliotropic lymphoma in a dog, Vet Dermatol ment of cutaneous epitheliotropic lymphoma in dogs? A critically
28:246–e265, 2017. appraised topic, BMC Vet Res 13:61, 2017.